Scientific Sessions 2024  /  Prevention of Injury and Improvement in Outcomes in the ACS Population  /  Mineralocorticoid receptor antagonist in patients with acute myocardial infarction: An updated systematic review and meta-analysis of randomized trials
Logo

American Heart Association

  141
  0

Final ID: MDP1709

Mineralocorticoid receptor antagonist in patients with acute myocardial infarction: An updated systematic review and meta-analysis of randomized trials

Abstract Body (Do not enter title and authors here): Background: While mineralocorticoid antagonists (MRA) reduce mortality in patients developing heart failure post myocardial infarction (MI), it is unclear whether they are beneficial in an unselected post-MI population.

Aims: Using a systematic review and meta-analysis, we aim to determine the effect of MRA treatment versus no MRA treatment on all-cause mortality in unselected post-MI patients from randomized data, simultaneously with the presentation of the largest randomized controlled trial on the topic, the CLEAR SYNERGY trial.

Methods/Approach: We completed a systematic review of all randomized controlled trials comparing MRA treatment to no MRA treatment in post-MI patients. We will perform our primary analysis using fixed effects with the Peto odds ratio method and use random effects as a sensitivity analysis. The primary outcome will be all-cause mortality, and secondary outcomes will include cardiovascular mortality, new or worsening heart failure, recurrent myocardial infarction and stroke.

Results/Data: Our systematic review of Pubmed, Embase, and CENTRAL from inception until April 30, 2024, yielded 456 records. A total of 11,199 participants from 11 randomized clinical trials will be included in addition to the late-breaking CLEAR SYNERGY trial. The CLEAR SYNERGY trial is a 2 x 2 factorial randomized controlled trial of low-dose colchicine 0.5mg daily versus placebo and spironolactone 25mg daily versus placebo in 7,062 post-MI patients who were within 72h of the index percutaneous coronary intervention. The results of the spironolactone factorial will be presented in the fall of 2024 with an expected median follow-up of 3.5 years. As the investigators of the CLEAR SYNERGY trial, we will combine our data with the other 11 trials for a total of 12 trials and 18,261 participants.

Conclusions: CLEAR SYNERGY is the largest randomized controlled trial with the longest follow-up of spironolactone in the post-MI population. Our meta-analysis will provide updated effect estimates of post-MI MRA treatment, leveraging the late-breaking CLEAR SYNERGY data to reflect the totality of the evidence.
  • D'entremont, Marc-andre  ( Population Health Research Institute , Hamilton , Ontario , Canada )
  • Cheema, Zain  ( McMaster University , Hamilton , Ontario , Canada )
  • Chauhan, Ashwin  ( McMaster University , Hamilton , Ontario , Canada )
  • Kedev, Sasko  ( University Clinic of Cardiology , Skopje , Macedonia (the former Yugoslav Republic of) )
  • Cornel, Jan  ( Radboudumc , Nijmegen , Netherlands )
  • Stankovic, Goran  ( Univ. Clinical Center of Serbia , Belgrade , Serbia )
  • Moreno, Raul  ( University Hospital La Paz, Madrid, , Madrid , Spain )
  • Storey, Robert  ( UNIVERSITY SHEFFIELD MEDICAL SCHOOL , Sheffield , United Kingdom )
  • Bossard, Matthias  ( Luzerner Kantonsspital , Luzerne , Switzerland )
  • Montalescot, Gilles  ( HOPITAL PITIE SALPETRIERE , Paris , France )
  • Zannad, Faiez  ( CVCT and Universite de Lorraine , Paris , France )
  • Beygui, Farzin  ( CHU CAEN , Caen , France )
  • Pitt, Bertram  ( University of Michigan School , Ann Arbor , Michigan , United States )
  • Jolly, Sanjit  ( Population Health Research Institute , Hamilton , Ontario , Canada )
    • Author Disclosures:
    Marc-Andre d'Entremont: DO NOT have relevant financial relationships | Gilles Montalescot: DO have relevant financial relationships ; Other (please indicate in the box next to the company name):Abbott : research or educational grant to the institution and consulting or lecture fees:Active (exists now) ; Other (please indicate in the box next to the company name):Terumo : research or educational grant to the institution and consulting or lecture fees:Past (completed) ; Other (please indicate in the box next to the company name):SMT : research or educational grant to the institution and consulting or lecture fees:Past (completed) ; Other (please indicate in the box next to the company name):Pfizer:Active (exists now) ; Other (please indicate in the box next to the company name):Novo Nordisk : research or educational grant to the institution and consulting or lecture fees:Past (completed) ; Other (please indicate in the box next to the company name):Lilly:Past (completed) ; Other (please indicate in the box next to the company name):Idorsia:Active (exists now) ; Other (please indicate in the box next to the company name):Hexacath:Past (completed) ; Other (please indicate in the box next to the company name):CSL Behring : research or educational grant to the institution and consulting or lecture fees:Past (completed) ; Other (please indicate in the box next to the company name):Celecor : research or educational grant to the institution and consulting or lecture fees:Past (completed) ; Other (please indicate in the box next to the company name):Boehringer Ingelheim : research or educational grant to the institution and consulting or lecture fees:Active (exists now) ; Other (please indicate in the box next to the company name):BMS : research or educational grant to the institution and consulting or lecture fees:Active (exists now) ; Other (please indicate in the box next to the company name):Bayer : research or educational grant to the institution and consulting or lecture fees:Past (completed) ; Other (please indicate in the box next to the company name):AstraZeneca : research or educational grant to the institution and consulting or lecture fees:Past (completed) ; Other (please indicate in the box next to the company name):Amgen : research or educational grant to the institution and consulting or lecture fees:Past (completed) | Faiez ZANNAD: DO have relevant financial relationships ; Advisor:NovoNordisk:Past (completed) ; Advisor:Northsea:Expected (by end of conference) ; Advisor:Merck:Active (exists now) ; Advisor:CEVA:Past (completed) ; Advisor:Cellprothera:Active (exists now) ; Advisor:Cereno:Active (exists now) ; Ownership Interest:CVCT:Active (exists now) ; Advisor:Cardior:Past (completed) ; Advisor:CVRx:Active (exists now) ; Advisor:BMS:Past (completed) ; Advisor:Boehringer:Active (exists now) ; Advisor:Biopeutics:Active (exists now) ; Consultant:Owkin:Active (exists now) ; Advisor:Bayer:Active (exists now) ; Advisor:Applied Therapeutics:Past (completed) | Farzin Beygui: No Answer | Bertram Pitt: No Answer | Sanjit Jolly: No Answer | Zain Cheema: DO NOT have relevant financial relationships | Ashwin Chauhan: No Answer | Sasko Kedev: DO NOT have relevant financial relationships | Jan Cornel: No Answer | Goran Stankovic: DO NOT have relevant financial relationships | Raul Moreno: No Answer | Robert Storey: DO have relevant financial relationships ; Consultant:AstraZeneca:Active (exists now) ; Speaker:Tabuk:Past (completed) ; Consultant:Pfizer:Past (completed) ; Consultant:Novo Nordisk:Active (exists now) ; Consultant:Novartis:Past (completed) ; Consultant:Idorsia:Active (exists now) ; Consultant:Daiichi Sankyo:Past (completed) ; Consultant:Chiesi:Past (completed) ; Consultant:Boehringer Ingelheim/Lilly:Past (completed) ; Consultant:Alfasigma:Past (completed) ; Researcher:Cytosorbents:Active (exists now) ; Consultant:Cytosorbents:Active (exists now) ; Researcher:AstraZeneca:Active (exists now) | Matthias Bossard: No Answer
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Prevention of Injury and Improvement in Outcomes in the ACS Population

Monday, 11/18/2024 , 12:50PM - 02:15PM

Moderated Digital Poster Session

More abstracts on this topic:
Effect of finerenone on a hierarchical composite endpoint analyzed using win statistics in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of FINEARTS-HF.

Kondo Toru, Amarante Flaviana, Lam Carolyn, Senni Michele, Shah Sanjiv, Voors Adriaan, Zannad Faiez, Pitt Bertram, Vaduganathan Muthiah, Solomon Scott, Mcmurray John, Jhund Pardeep, Henderson Alasdair David, Claggett Brian, Desai Akshay, Brinker Meike, Lay-flurrie James, Schloemer Patrick, Viswanathan Prabhakar

A Personal Risk Assessment Device in Patients with Chest Pain

Shvilkin Alexei, Zlatic Natasa, Atanasoski Vladimir, Grujovic Zdolsek Sanja, Popovic Maneski Lana, Miletic Marjan, Vukcevic Vladan

More abstracts from these authors:
In-Depth: The CLEAR SYNERGY (OASIS 9) Trial: A 2x2 Factorial Randomized Controlled Trial of Colchicine versus placebo and Spironolactone versus placebo in Patients with Myocardial Infarction. The results of the spironolactone factorial

Jolly Sanjit, D'entremont Marc-andre

Discussant: REALIZE-K

Zannad Faiez, Allen Larry

You have to be authorized to contact abstract author. Please, Login
Not Available